This seems to be welcome news to patients with grass-induced allergic rhinitis. However, the tablets do not contain Bahia or Bermuda grass extracts, both of which are major grass allergens in the southeast. Additionally, neither Bahia nor Bermuda cross-reacts with Timothy vastly limiting the usefulness of this therapy in the south.
New Oral Immunotherapy for Grass Allergies Approved — Physician’s First Watch
New Oral Immunotherapy for Grass Allergies Approved
By Kristin J. Kelley
The FDA has approved Grastek, a second sublingual immunotherapy to treat grass pollen allergies. (The first sublingual immunotherapy for grass allergies, Oralair, was approved earlier this month.) The new tablet contains Timothy grass extracts and is indicated for patients aged 5 to 65 years.
In December 2013, FDA advisers called for postapproval studies to test Grastek's safety in children aged 5 to 11 years, citing side effects such as lip swelling and oral blistering.